Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.

Clear cell sarcoma of soft tissue (CCSST) represents a highly malignant tumor of the musculoskeletal system that is characterized by the chromosomal translocation t(12;22)(q13;q12) of the Ewing sarcoma gene (EWSR1) and activating transcription factor 1 (ATF1). In a former microarray expression study, we identified ERBB3, a member of the epidermal growth factor receptor (EGFR) family, as a promising new diagnostic marker in the differential diagnosis of CCSST. Here we show that, besides ErbB3, all CCSST cell lines (n = 8) also express the ErbB2 receptor or the ErbB4 receptor, representing an adequate coreceptor of ErbB3. The phosphorylation status of ErbB3 revealed these receptor pairs to be either constitutively activated in CCSST cells with high neuregulin-1 (NRG1) expression (n = 4) or activatable by exogenic NRG1 in cells showing low amounts of NRG1 mRNA (n = 4). Exogenous NRG1 stimulated the growth of a subset of CCSST cells but did not affect the kinetics of another subset. This difference was not strictly dependent on endogenous NRG1 expression; however, the growth-inhibiting effect of the pan-ErbB tyrosine kinase inhibitor CI-1033 or PD158780 clearly correlated with NRG1 expression indicating an autocrine growth stimulation loop which may constitute an interesting target of new therapeutic strategies in this tumor entity.

[1]  G. Thomas,et al.  EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts , 1993, Nature Genetics.

[2]  W. Grizzle,et al.  Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors , 2005, Oncogene.

[3]  A. Oza,et al.  Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Falls Neuregulins and the neuromuscular system: 10 years of answers and questions , 2003, Journal of neurocytology.

[5]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[6]  S. Ménard,et al.  Expression of HER/erbb family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells , 2000, International journal of cancer.

[7]  P. Ritch,et al.  Neuregulin‐1 enhances survival of human astrocytic glioma cells , 2005, Glia.

[8]  N. Hynes,et al.  The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.

[9]  I. Jacobs,et al.  Clear Cell Sarcoma: An Institutional Review , 2004, The American surgeon.

[10]  P. Swanson,et al.  Overexpression of the c-erbB-2 oncogene in sarcomas and small round-cell tumors of childhood. An immunohistochemical investigation. , 1992, Archives of pathology & laboratory medicine.

[11]  F. Sim,et al.  Clear Cell Sarcoma of Soft Tissues: Mayo Clinic Experience With 35 Cases , 1992, The American journal of surgical pathology.

[12]  G Konecny,et al.  The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. , 2000, Cancer treatment and research.

[13]  M. Iorio,et al.  Role of HER receptors family in development and differentiation , 2004, Journal of cellular physiology.

[14]  C. Lundsteen,et al.  Deletions below 10 megabasepairs are detected in comparative genomic hybridization by standard reference intervals , 1999, Genes, chromosomes & cancer.

[15]  W. Winkelmann,et al.  Population-based genetic alterations in Ewing's tumors from Japanese and European Caucasian patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Y. Yarden The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[17]  Stephen L. Abrams,et al.  The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what’s genetics got to do with it? , 2005, Expert opinion on therapeutic targets.

[18]  Toshifumi Ozaki,et al.  Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. , 2002, International journal of oncology.

[19]  A. Ferrari,et al.  Clear cell sarcoma of tendons and aponeuroses in pediatric patients , 2002, Cancer.

[20]  P. Picci,et al.  Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. , 2005, European journal of cancer.

[21]  M. Gross,et al.  Targeting the HER-kinase axis in cancer. , 2004, Seminars in oncology.

[22]  J. W. Finley,et al.  Clear cell sarcoma: The Roswell Park experience , 2001, Journal of surgical oncology.

[23]  G. Reifenberger,et al.  Expression Profiling of t(12;22) Positive Clear Cell Sarcoma of Soft Tissue Cell Lines Reveals Characteristic Up-Regulation of Potential New Marker Genes Including ERBB3 , 2004, Cancer Research.

[24]  D. Wai,et al.  Characterization of the malignant melanoma of soft-parts cell line GG-62 by expression analysis using DNA microarrays , 2002, Virchows Archiv.

[25]  T. Giordano,et al.  Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  E. van Marck,et al.  Malignant melanoma of soft parts. Further cytogenetic characterization. , 1992, Cancer genetics and cytogenetics.

[27]  F. Enzinger,et al.  Malignant melanoma of soft parts: A reassessment of clear cell sarcoma* , 1983, The American journal of surgical pathology.

[28]  William Stafford Noble,et al.  Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Lundsteen,et al.  Detection of chromosomal gains and losses in comparative genomic hybridization analysis based on standard reference intervals. , 1998, Cytometry.

[30]  M. Fritsch,et al.  Genetic analysis of mediastinal nonseminomatous germ cell tumors in children and adolescents , 2002, Genes, chromosomes & cancer.

[31]  D. Pinkel,et al.  Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .

[32]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.